We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+33.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.72B
AUM Growth
-$71.4M
Cap. Flow
-$452M
Cap. Flow %
-16.6%
Top 10 Hldgs %
41.91%
Holding
86
New
16
Increased
22
Reduced
27
Closed
9

Top Buys

Rank Stock Value
1
SLN
Silence Therapeutics
SLN
+$44.1M
2
KROS icon
Keros Therapeutics
KROS
+$32.8M
3
FDMT icon
4D Molecular Therapeutics
FDMT
+$32.2M
4
CI icon
Cigna
CI
+$21.5M
5
IMNM icon
Immunome
IMNM
+$20.5M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$487M
2
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$115M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$67.7M
4
KRYS icon
Krystal Biotech
KRYS
+$31.2M
5
CTLT
CATALENT, INC.
CTLT
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.54%
2 Industrials 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOOK
76
DELISTED
HOOKIPA Pharma
HOOK
$757K 0.03%
106,377
– –
TKNO icon
77
Alpha Teknova
TKNO
$291M
$434K 0.02%
171,453
+10,448
+6% +$32.4K
CRL icon
78
Charles River Laboratories
CRL
$10.8B
– –
-86,782
Closed -$20.5M
SPY icon
79
State Street SPDR S&P 500 ETF Trust
SPY
$774B
– –
-142,500
Closed -$67.7M
BCEL
80
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-442,653
Closed -$58.4K
SNCE
81
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-990,412
Closed -$5.29M
RYZB
82
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-1,857,706
Closed -$115M
MDVL
83
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
– –
-692,082
Closed -$3.05M
IMGN
84
DELISTED
Immunogen Inc
IMGN
– –
-16,423,922
Closed -$487M
NVTA
85
DELISTED
Invitae Corporation
NVTA
– –
-1,474,026
Closed -$924K
SLGC
86
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-370,839
Closed -$938K
1 2 3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q1 2024 Portfolio in Review

As of Q1 2024, Redmile Group held 86 positions worth $2.72B, down 2.6% from $2.8B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $452M in Q1 2024, closing 9 positions and reducing 27 holdings. Its most notable exit was Immunogen Inc, an estimated $487M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in Silence Therapeutics worth $43.8M.

  • Redmile Group's largest Q1 2024 buy was Silence Therapeutics: 2,027,669 shares worth $43.8M.
  • Redmile Group added most to Immunome in Q1 2024, an estimated $20.5M increase.
  • Redmile Group's biggest Q1 2024 reduction was Krystal Biotech, cutting an estimated $31.2M.
  • Redmile Group fully exited Immunogen Inc in Q1 2024, selling an estimated $487M.
  • Redmile Group's ten largest holdings make up 42% of its $2.72B portfolio in Q1 2024.
  • Redmile Group opened 16 new positions and closed 9 in Q1 2024.
  • Redmile Group's portfolio value fell 2.6% quarter-over-quarter to $2.72B.

Based on Redmile Group's 13F filing for Q1 2024, filed 15 May 2024.